FAM
AMLX icon

Fulcrum Asset Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Fulcrum Asset Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$82.3K Buy
+4,400
New +$68K 0.01% 518

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Fulcrum Asset Management's AMLX Position: Q2 2026 in Review

Fulcrum Asset Management opened a new position in Amylyx Pharmaceuticals (AMLX) in Q2 2026: 4,400 shares worth $82.3K. The stake represents 0.01% of the portfolio and ranks #518 among its holdings.

206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Fulcrum Asset Management held 4,400 shares of Amylyx Pharmaceuticals worth $82.3K as of Q2 2026.
  • Amylyx Pharmaceuticals was a new Fulcrum Asset Management position in Q2 2026.
  • Amylyx Pharmaceuticals made up 0.01% of Fulcrum Asset Management's portfolio in Q2 2026, its #518 holding.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Fulcrum Asset Management's 13F filing for Q2 2026, filed 18 Aug 2026.